0.63
-0.1996(-24.06%)
Currency In USD
| Previous Close | 0.83 |
| Open | 0.77 |
| Day High | 0.78 |
| Day Low | 0.61 |
| 52-Week High | 2.53 |
| 52-Week Low | 0.24 |
| Volume | 3.53M |
| Average Volume | 944,350 |
| Market Cap | 37M |
| PE | -0.57 |
| EPS | -1.1 |
| Moving Average 50 Days | 0.6 |
| Moving Average 200 Days | 0.46 |
| Change | -0.2 |
If you invested $1000 in BioAtla, Inc. (BCAB) since IPO date, it would be worth $20.31 as of October 20, 2025 at a share price of $0.63. Whereas If you bought $1000 worth of BioAtla, Inc. (BCAB) shares 3 years ago, it would be worth $94.33 as of October 20, 2025 at a share price of $0.63.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
GlobeNewswire Inc.
9 hours ago
Adverse events (AEs) generally transient and readily manageable; only 2 cases of cytokine release syndrome (CRS)Prolonged tumor control with increasing doses of BA3182; confirmed partial response (cPR) at 0.6 mg in a patient with intrahepatic cholang
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
GlobeNewswire Inc.
Oct 03, 2025 1:00 PM GMT
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA
GlobeNewswire Inc.
Sep 08, 2025 12:00 PM GMT
FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approvalCompany continues preparations for enabling initiation of the Phase 3 study with the goal of advancing t